Quest Partners LLC Sells 14,574 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Quest Partners LLC cut its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 60.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,645 shares of the company’s stock after selling 14,574 shares during the period. Quest Partners LLC’s holdings in Recursion Pharmaceuticals were worth $64,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of RXRX. Axxcess Wealth Management LLC increased its position in Recursion Pharmaceuticals by 4.3% during the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares during the last quarter. Green Alpha Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 2.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after purchasing an additional 1,800 shares during the last quarter. Interchange Capital Partners LLC lifted its stake in shares of Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after purchasing an additional 2,349 shares during the period. Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares during the period. 89.06% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.27, for a total transaction of $71,772.69. Following the transaction, the director now directly owns 7,121,322 shares in the company, valued at $44,650,688.94. This trade represents a 0.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. This represents a 2.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 165,682 shares of company stock valued at $1,088,111 in the last ninety days. 15.75% of the stock is owned by company insiders.

Analyst Ratings Changes

RXRX has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, November 20th. Jefferies Financial Group cut their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Finally, Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $7.07 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $15.74. The business has a 50 day simple moving average of $6.57 and a two-hundred day simple moving average of $7.40. The stock has a market capitalization of $2.03 billion, a PE ratio of -4.62 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.43) earnings per share. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.